1 documents found
Information × Registration Number 0107U012633, R & D request Title Randomized, double blind, placebo-controlled, multicentered investigation for efficacy, safety and tolerance evaluation of Likarbasepin 750-2000 mg a day as addition to atypical antipsychotics in treatment of maniacal attacks of manic-depressive psychosis Type I for 6 weeks and 52-week open extended clinical research performed to evaluate safety and tolerance to Likarbasepin 750-2500mg per day in treatment of maniacal attacks of manic-depressive psychosis Type I Head Кузнецов Валерій Миколайович, Registration Date 27-12-2007 Organization Shupyk National Medical Academy of Postgraduate Education popup.description1 popup.nrat_date 2024-12-10 Close
search.res_rk
Randomized, double blind, placebo-controlled, multicentered investigation for efficacy, safety and tolerance evaluation of Likarbasepin 750-2000 mg a day as addition to atypical antipsychotics in treatment of maniacal attacks of manic-depressive psychosis Type I for 6 weeks and 52-week open extended clinical research performed to evaluate safety and tolerance to Likarbasepin 750-2500mg per day in treatment of maniacal attacks of manic-depressive psychosis Type I
Head: Кузнецов Валерій Миколайович. Randomized, double blind, placebo-controlled, multicentered investigation for efficacy, safety and tolerance evaluation of Likarbasepin 750-2000 mg a day as addition to atypical antipsychotics in treatment of maniacal attacks of manic-depressive psychosis Type I for 6 weeks and 52-week open extended clinical research performed to evaluate safety and tolerance to Likarbasepin 750-2500mg per day in treatment of maniacal attacks of manic-depressive psychosis Type I. Shupyk National Medical Academy of Postgraduate Education. № 0107U012633
1 documents found

Updated: 2026-03-21


Роздрукувати цю сторінку